Pharma-2012 conference focuses on regulatory affairs
Sachin Jagdale – Hyderabad
Dr Shivanand Puthli receives ‘Distinguished Scientist Award’ from Dr Srinubabu Gedela |
The 2nd International Conference of Pharma-ceutical Regulatory Affairs (Pharma-2012) concluded recently at Hyderabad International Convention Center (HICC). The two-day conference was organised by OMICS Group, which was attended by industry stalwarts and students from all across the country. There were participants from overseas countries as well.
Dr Srinubabu Gedela, Founding Director, OMICS Group, US said, “The main objective to organise Pharma-2012 was to provide a platform for domestic and international players to share and discuss contemporary issues related to the pharma industry with an aim to standardise quality guidelines and safety regulations.”
Dr Jayaprakash Narayan, President, Lok Satta Party and Member of Legislative Assembly, Andhra Pradesh, shared his views on regulations in the pharma industry. Being a student of biology, he blended his past experiences to overcome the challenges in future. Narayan said, “A century ago we had very little knowledge to share about the budding technologies of that period such as vaccines, recombination etc. But today history has left us with valuable experiences where a technology can be a pro or a con.”
Narayan focused on the need for efficacy, safety and cost effectiveness in the field of pharma. He adds, “Careful intervention and regulatory thought process is required to accept a novel technique today. Companies are carrying a great hope along with an intense fear in the process of drug discovery and it proved that a failure at any step can be a huge set back not only for the drug but in the economic status of an organisation. Higher cost does not bring higher benefits.”
Following the speech of Narayan, other guests, D Prakash Nagara Katti, President-Research, University of South Carolina, US; Prof Patrick Leoni, Euromed Management, France, Prof Jagat R Kanwar, Director-Research Council, Deakin University, Australia and Dr Michael Alexender, Director-MIDI, US also discussed the importance of regulatory affairs in the pharma industry.
Pharma-2012 conference was designed to help gaining a new vision of current and emerging regulatory prospects and new ideas to build regulatory systems. The two-day conference had four parallel scientific sessions with about 150 lectures and 300 poster presentations. “With more than 700 delegates from 25 countries participation, Pharma-2012 promised to be the door to opportunities of a dynamic mix of high profile industry thought leaders, policy makers and other key stakeholders of the industry and academia,” said Dr Ravi Kumar Dasari, Head – OMICS Group Conferences.
According to the participants, the main highlights of the conference were discussions on regulatory affairs for healthcare products, safety and quality regulation, law enforcement and education. Speakers also spoke about biomedical intellectual property management and novel strategies for growth in the pharma and regulatory environment.